Nanocell attack: new combo therapy takes on tough pancreatic cancer

NCT ID NCT07049055

Recruiting now Disease control Sponsor: Engeneic Pty Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding specially designed nanocells (tiny particles that deliver a potent drug directly to cancer cells) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 144 adults whose cancer has worsened despite prior treatment will receive either the nanocell combo or chemo alone. The goal is to see if the new approach is safe and improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression malignant pancreatic neoplasm Neoplasm Metastasis pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER METASTATIC PDAC - PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Locations

Atlantic Health
RECRUITING

Summit, New Jersey, 07901, United States
Chan Soon-Shiong Institute for Medicine
ACTIVE_NOT_RECRUITING

El Segundo, California, 90245, United States
Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States

Contact Email: •••••@•••••
Taylor Cancer Center
RECRUITING

Maumee, Ohio, 43537, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.